A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

G Hess; Martin Dreyling; L Oberic; E Gine; PL Zinzani; KM Linton; A Vilmar; M Jerkeman; JMH Chen; A Ohler; S Stilgenbauer; Catherine Thieblemont; J Lambert; VR Zilioli; JM Sancho; A Jimenez-Ubieto; L Fischer; TA Eyre; S Keeping; JE Park; JJ Wu; R Siddiqi; J Reitan; G Castaigne; G Salles

doi:10.1182/blood-2022-162638

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

G Hess, Martin Dreyling, L Oberic, E Gine, PL Zinzani, KM Linton, A Vilmar, M Jerkeman, JMH Chen, A Ohler, S Stilgenbauer, Catherine Thieblemont, J Lambert, VR Zilioli, JM Sancho, A Jimenez-Ubieto, L Fischer, TA Eyre, S Keeping, JE ParkJJ Wu, R Siddiqi, J Reitan, G Castaigne, G Salles

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	10296-10299
Number of pages	4
Journal	Blood
Volume	140
DOIs	https://doi.org/10.1182/blood-2022-162638
Publication status	Published - 15 Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2022-162638

Cite this

Hess, G., Dreyling, M., Oberic, L., Gine, E., Zinzani, PL., Linton, KM., Vilmar, A., Jerkeman, M., Chen, JMH., Ohler, A., Stilgenbauer, S., Thieblemont, C., Lambert, J., Zilioli, VR., Sancho, JM., Jimenez-Ubieto, A., Fischer, L., Eyre, TA., Keeping, S., ... Salles, G. (2022). A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). Blood, 140, 10296-10299. https://doi.org/10.1182/blood-2022-162638

Hess, G ; Dreyling, Martin ; Oberic, L et al. / A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). In: Blood. 2022 ; Vol. 140. pp. 10296-10299.

@article{886f899de2b848c1992cb30ba94b4f1a,

title = "A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)",

author = "G Hess and Martin Dreyling and L Oberic and E Gine and PL Zinzani and KM Linton and A Vilmar and M Jerkeman and JMH Chen and A Ohler and S Stilgenbauer and Catherine Thieblemont and J Lambert and VR Zilioli and JM Sancho and A Jimenez-Ubieto and L Fischer and TA Eyre and S Keeping and JE Park and JJ Wu and R Siddiqi and J Reitan and G Castaigne and G Salles",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-162638",

language = "English",

volume = "140",

pages = "10296--10299",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

Hess, G, Dreyling, M, Oberic, L, Gine, E, Zinzani, PL, Linton, KM, Vilmar, A, Jerkeman, M, Chen, JMH, Ohler, A, Stilgenbauer, S, Thieblemont, C, Lambert, J, Zilioli, VR, Sancho, JM, Jimenez-Ubieto, A, Fischer, L, Eyre, TA, Keeping, S, Park, JE, Wu, JJ, Siddiqi, R, Reitan, J, Castaigne, G & Salles, G 2022, 'A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)', Blood, vol. 140, pp. 10296-10299. https://doi.org/10.1182/blood-2022-162638

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). / Hess, G; Dreyling, Martin; Oberic, L et al.
In: Blood, Vol. 140, 15.11.2022, p. 10296-10299.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

AU - Hess, G

AU - Dreyling, Martin

AU - Oberic, L

AU - Gine, E

AU - Zinzani, PL

AU - Linton, KM

AU - Vilmar, A

AU - Jerkeman, M

AU - Chen, JMH

AU - Ohler, A

AU - Stilgenbauer, S

AU - Thieblemont, Catherine

AU - Lambert, J

AU - Zilioli, VR

AU - Sancho, JM

AU - Jimenez-Ubieto, A

AU - Fischer, L

AU - Eyre, TA

AU - Keeping, S

AU - Park, JE

AU - Wu, JJ

AU - Siddiqi, R

AU - Reitan, J

AU - Castaigne, G

AU - Salles, G

PY - 2022/11/15

Y1 - 2022/11/15

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000893230303139&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1182/blood-2022-162638

DO - 10.1182/blood-2022-162638

M3 - Meeting Abstract

SN - 0006-4971

VL - 140

SP - 10296

EP - 10299

JO - Blood

JF - Blood

ER -

Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton KM et al. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). Blood. 2022 Nov 15;140:10296-10299. doi: 10.1182/blood-2022-162638

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

UN SDGs

Access to Document

Other files and links

Cite this